Dengue virus 4/2 envelope domain chimeric virus panel maps type-specific responses against dengue serotype 2
mBio · 31.10.2023 · 14 (5)
DOI: 10.1128/mbio.00818-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 31.10.2023. Verfasst von Deanna R Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Dengue Virus, Dengue. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The DENV envelope (E) and pre-membrane (prM) glycoproteins are primary targets of serologic immunity after infection and vaccination. Of these, serotype-specific (TS) antibodies typically target E domains, while serotype cross-reactive (CR) antibodies typically the target prM protein and conserved E regions. To identify and quantify E-domain TS neutralizing antibody responses in polyclonal sera, we developed a panel of chimeric DENV4/2 viruses that incorporate DENV2 envelope domain I, II, and III (DENV4/2-EDI, EDII, EDIII) into the DENV4 E glycoprotein. Chimeric DENV4/2 viruses were recovered, replicated efficiently, and displayed similar maturation states as parental viruses. The recovery of viable DENV4/2-EDII recombinants required the inclusion of chimeric DENV4/2 prM that maintained critical interactions with chimeric E. To assess structural integrity and epitope display of chimeric viruses, we examined neutralization of mature virions by monoclonal antibodies (mAbs) and heterotypic polyclonal sera. The ED-chimeric virions preserved epitopes of TS and envelope-dimer-epitope CR mAbs and had similar sensitivity to CR polyclonal responses as parental strains. Primary sera from natural infection and human challenge target a region centered on EDIII and secondarily target EDII and EDI. Sera from natural infection had a unique neutralization pattern compared to sera from human challenge, which included greater frequency and higher titer of responses against DENV EDII. In summary, DENV4/2 E recombinant viruses delineate the subdomain targets of TS antibodies after vaccination and primary infection, which may provide new correlates of protection or identify epitopes of neutralizing monoclonal antibodies. IMPORTANCE The four dengue virus (DENV) serotypes infect several hundred million people each year. Although primary infection is generally mild, subsequent infection by differing serotypes increases the risk for symptomatic disease ranging from fever to life-threatening shock. Despite the availability of licensed vaccines, a comprehensive understanding of antibodies that target the viral envelope protein and protect from infection remains incomplete. In this manuscript, we develop a panel of recombinant viruses that graft each envelope domain of DENV2 onto the DENV4 envelope glycoprotein, revealing protein interactions important for virus viability. Furthermore, we map neutralizing antibody responses after primary DENV2 natural infection and a human challenge model to distinct domains on the viral envelope protein. The panel of recombinant viruses provides a new tool for dissecting the E domain-specific targeting of protective antibody responses, informing future DENV vaccine design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA.
- Department of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University , St. Louis, Missouri, USA.
- College of Science, Engineering and Food Science, University College Cork , Cork, Ireland.
- Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA.
ORCID-Profile: Deanna R Zhu, Ralph S Baric
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Zhu, D. R., Rajesh, A. J., Meganck, R. M., Young, E. F., Munt, J. E., Tse, V. L., Yount, B., Conrad, H., White, L., Henein, S., DeSilva, A. M., & Baric, R. S. (2023). Dengue virus 4/2 envelope domain chimeric virus panel maps type-specific responses against dengue serotype 2. mBio, 14(5). https://doi.org/10.1128/mbio.00818-23
Vancouver
Zhu DR, Rajesh AJ, Meganck RM, Young EF, Munt JE, Tse VL, et al. Dengue virus 4/2 envelope domain chimeric virus panel maps type-specific responses against dengue serotype 2. mBio. 2023;14(5). doi:10.1128/mbio.00818-23
BibTeX
@article{Zhu2023,
author = {Zhu, Deanna R and Rajesh, Alecia J and Meganck, Rita M and Young, Ellen F and Munt, Jennifer E and Tse, Victor L and Yount, Boyd and Conrad, Helen and White, Laura and Henein, Sandra and DeSilva, Aravinda M and Baric, Ralph S},
title = {Dengue virus 4/2 envelope domain chimeric virus panel maps type-specific responses against dengue serotype 2},
journal = {mBio},
year = {2023},
volume = {14},
number = {5},
doi = {10.1128/mbio.00818-23}
}
EUVIMED